Related Experiment Video
Updated: May 21, 2026
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Guideline for the diagnosis and management of myelofibrosis
John T Reilly1, Mary Frances McMullin, Philip A Beer
1Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. j.t.reilly@sheffield.ac.uk
Insights
This guideline offers UK healthcare professionals clear recommendations for diagnosing and managing myelofibrosis, including primary, post-polycythaemic MF, and post-thrombocythemic MF in all age groups.
Area of Science:
- Hematology
- Clinical Guidelines
- Evidence-Based Medicine
Background:
- Myelofibrosis diagnosis and management require updated, evidence-based guidance.
- Existing guidelines may not cover all subtypes or age groups comprehensively.
Framework:
- Developed by UK hematology experts with US input.
- Systematic literature search of MEDLINE and EMBASE (1966-2011).
- Guideline drafted and revised by consensus through British Committee for Standards in Haematology (BCSH) task forces.
Implementation:
- Incorporated feedback from UK hematologists and BCSH committees.
- Utilized the GRADE system for evidence strength and quality assessment.
- Evidence levels and grades align with BCSH guideline procedures.
Implications:
- Provides clear guidance for investigating and managing primary myelofibrosis.
- Addresses management of post-polycythaemic myelofibrosis (post-PV MF) and post-thrombocythemic myelofibrosis (post-ET MF).
- Applicable to both adult and pediatric patients, ensuring comprehensive care.
Abstract:
The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematically for publications in English from 1966 until August 2011 using a variety of key words. The writing group produced the draft guideline, which was subsequently revised by consensus of the members of the General Haematology and Haemato-oncology Task Forces of the British Committee for Standards in Haematology (BCSH). The guideline was then reviewed by a sounding board of UK haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The criteria used to state levels and grades of evidence are as outlined in the Procedure for Guidelines commissioned by the BCSH; the 'GRADE' system was used to score strength and quality of evidence. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of primary myelofibrosis, as well as post-polycythaemic myelofibrosis (post-PV MF) and post-thrombocythemic myelofibrosis (post-ET MF) in both adult and paediatric patients.
More Related Videos
07:53Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
